On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Developing Novel Treatment Options for Cancer Patients in Booming Market Forecasted to Reach $145 Billion by 2022

Company: BriaCell Therapeutics Corp. (BCTXF)
Category: Stock Spotlights

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, is currently developing immunotherapy solutions demonstrated to be highly effective and well tolerated by patients. The market share for immunotherapy treatments for breast cancer as well as other malignancies is forecasted to surge in the coming years. An article discussing the company reads, “Several studies indicate that the incidence of breast cancer is expected to increase in the next decade (http://nnw.fm/o92YV). U.S. breast cancer diagnoses are anticipated to grow from 283,000 in 2011 to 441,000 in 2030, an increase of over 50 percent. The proportion of cases diagnosed among women in the 50–to–69 age group is expected to decrease from 55 percent to 44 percent in 2030. Diagnoses among those aged 70 to 84, however, will increase from 24 percent to 35 percent. . . . Immunotherapy could provide a viable solution to the problem. The cancer immunotherapy market is anticipated to grow to $145 billion by 2022, at a CAGR of 14 percent (http://nnw.fm/gXWO3).  Immunotherapy currently accounts for 50 percent of the oncology medications market, but it is forecast that roughly 60 percent of previously treated cancer patients will adopt immunotherapy by 2026.”

To view the full article, visit http://nnw.fm/O6Iu7

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Contact us: 212.418.1217